{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:43Z","timestamp":1787010163363,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"none","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>By increasing life expectancy of people living with HIV, the most clinical challenge is managing both drug-to-drug interactions and comorbidities (especially metabolic). Doravirine (DOR), a new non-nucleoside reverse transcriptase inhibitor, recently approved for the treatment of HIV, could be a good companion of dolutegravir (DTG) in a dual regimen for experienced elderly patients with multimorbidity and polypharmacy.<\/jats:p>\n                    <jats:p>We herein report our preliminary experience in a small cohort of elderly patients (&gt;50\u200ayears of age) with multimorbidity and on polypharmacy who were switched to DOR\/DTG dual regimen and followed-up for 3 months. The study was conducted at the Infectious and Tropical Diseases Unit of Padua University Hospital, Italy.<\/jats:p>\n                    <jats:p>Eighteen patients were included, 72.2% males and 27.8% postmenopausal women, mean age was of 61.3\u200ayears (7.6), 50% experienced AIDS events. Switches to DOR and DTG were mainly due to high cardiovascular and metabolic risk (72.2%), and interactions among comedications (50%). Antiretrovirals that subjects were switched off were mostly boosted protease inhibitors 66.7%. We observed a viral suppression among all subjects. Interestingly, we observed a statistically significant reduction in body mass index, body weight and waist circumference, eGFR, and a significant increase in serum creatinine levels. No significant changes in CD4+ T cell count was observed from the baseline. Lipid and fasting glucose values did not change significantly.<\/jats:p>\n                    <jats:p>To the best of our knowledge this is the first experience reporting real-life outcome of switch to DTG\u200a+\u200aDOR in elderly with multimorbidity and on polypharmacy. From our very preliminary data the dual combination of DTG and DOR could be a good treatment strategy for these subjects. However, our findings need to be validated on a greater number of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000028488","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T10:35:52Z","timestamp":1640860552000},"page":"e28488","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"first","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, Padua, Italy"},{"name":"Magna Graecia University of Catanzaro, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolita","family":"Sasset","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Leoni","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Putaggio","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hiv.12878","article-title":"2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0","volume":"10","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for the treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral na\u00efve adults with HIV-1 (DRIVE FORWARD): 96\u200aweeks results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-na\u00efve adults with Human Immundeficiency Virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD non inferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"Brief report: switching to DOR\/3TC\/TDF mantains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial","volume":"87","author":"Kumar","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-20250504","first-page":"201","article-title":"Doravirine and its potential in the treatment of HIV: an evidence-based review of the emerging data","volume":"12","author":"Rock","year":"2020","journal-title":"HIV\/AIDS"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2042098619880122","DOI":"10.1177\/2042098619880122","article-title":"Prescribing issues in older adults with HIV: thinking beyond drug-drug interactions with antiretroviral agents","volume":"10","author":"Livio","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"R8-20250504","article-title":"Evaluation of a clinic dedicated to people aging with HIV at Chelsea and Westminister Hospital: results of a 10-year experience","author":"Pereira","year":"2021","journal-title":"AIDS Res Hum Retrovir"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/eurpub\/cky098","article-title":"Defining and measuring multimorbidity: a systematic review of systematic reviews","volume":"29","author":"Johnston","year":"2019","journal-title":"Eur J Public health"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC geriatr"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"ofw053","DOI":"10.1093\/ofid\/ofw053","article-title":"Evaluation of serum creatinine changes with integrase inhibitors use in Human Immunodeficiency Virus-1 infected adults","volume":"3","author":"Lindeman","year":"2016","journal-title":"Open Forum Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:03:50Z","timestamp":1746317030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028488"}},"subtitle":["A retrospective analysis"],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":11,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028488","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]},"assertion":[{"value":"2021-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}